News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Peplin Inc. Completes Enrolment in its Phase 3 Clinical Trials for PEP005 Gel in AK on the Face and Scalp



7/7/2009 9:09:59 AM

EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced the completion of enrolment of its two Phase 3 clinical trials for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on head treatment areas, which include the face and scalp.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES